Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

Key Takeaways MRK now sees 2025 revenues of $64.3B-$65.3B with a reduced currency drag of about 0.5%.Keytruda sales rose 9% to $7.96B in Q2, about half of MRK's pharma revenues.Winrevair and Capvaxive posted solid growth and are seen as future growth drivers.Merck (MRK) announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same for sales. Meanwhile, despite a less negative impact from currency, Merck narrowed its sales guidance for 2025. The company, ho ...